Aim Immunotech SEC Filings

AIM ImmunoTech Inc. is offering 7,519,351 shares of Common Stock at $0.325 per share pursuant to a prospectus supplement, with estimated net proceeds of approximately $2.2 million.

In a concurrent private placement (exempt from this prospectus), the company is also offering Series I Common Warrants to purchase up to 15,038,702 shares at an exercise price of $0.325 per share; the warrants become exercisable only upon stockholder approval and expire five years after the Stockholder Approval Date. The offering is being conducted on a reasonable best efforts basis with Ladenburg Thalmann & Co. Inc. acting as sole placement agent.

AIM Immunotech Inc. supplements its prospectus to suspend its at-the-market equity distribution agreement and terminate the continuous offering. The Prospectus had registered the offer and sale of up to $3,409,174 of common stock under an Equity Distribution Agreement with Maxim Group LLC. As of this supplement dated May 19, 2026, the company reports $2,847,151.09 of common stock sold under the EDA and a last reported sale price of $0.4080 per share on May 18, 2026. The supplement states the company will not make any sales under the EDA unless and until a new prospectus supplement is filed; the EDA itself remains in full force and effect.

AIM ImmunoTech Inc. extended the maturity of its promissory note with Streeterville Capital, LLC to June 30, 2027, improving near-term debt obligations. The note’s outstanding balance following a $10,000 extension fee is about $1.68 million.

The company also reported stockholder equity of approximately $2.1 million as of March 31, 2026, a swing of roughly $11.9 million from a stockholder deficit of about $9.8 million as of December 31, 2025. AIM links this stronger equity position and the note extension to supporting its pancreatic cancer development program and other strategic initiatives.

AIM ImmunoTech reported a first-quarter 2026 net loss of $3.0M on minimal revenues of $22K, reflecting its development-stage status. Operating expenses fell sharply to $2.2M from $3.6M a year earlier, mainly from lower research and general and administrative costs.

Cash and cash equivalents increased to $5.8M at March 31, 2026 from $3.0M at year-end 2025, helped by equity sales, warrant exercises and a $1.8M Series G preferred stock rights offering. Stockholders’ equity improved from a deficit of $(9.8)M to positive equity of $2.1M, aided by an $8.7M reclassification of Class E and F warrants from liability to equity.

The company still faces significant risk: management notes substantial doubt about its ability to continue as a going concern, with working capital constraints, ongoing losses and stockholders’ equity of $2.1M versus the $6M minimum required to maintain NYSE American listing. It relies on additional financings, including Streeterville promissory notes and at-the-market equity sales, while advancing Ampligen for late-stage pancreatic cancer through the DURIPANC Phase 2 study and planning a Phase 3 trial with Thermo Fisher Scientific’s PPD unit.

AIM ImmunoTech Inc. filed a report highlighting a Virtual Investor Key Opinion Leader segment focused on Ampligen (rintatolimod) for late-stage pancreatic cancer. The segment features Professor Casper H.J. van Eijck of Erasmus Medical Center and AIM’s CEO discussing Ampligen’s mechanism, clinical data and development strategy.

The company recaps prior Named Patient Program results suggesting longer progression-free survival and overall survival versus historical controls, and notes ongoing Phase 2 DURIPANC trial work with AstraZeneca’s Imfinzi in metastatic pancreatic cancer. The press release and video segment are furnished, not filed, and include customary forward-looking statement cautions.

AIM ImmunoTech Inc. Schedule 13G shows Orca Capital beneficially owns 1,793,999 shares of common stock, representing 9.9% of the class immediately after the issuer's warrant inducement transaction.

The filing states the ownership calculation is based on 17,369,915 shares outstanding after the inducement and excludes 1,333,131 shares issuable upon exercise of common warrants, which are subject to the verbatim "9.99% Blocker".

AIM ImmunoTech Inc. completed a warrant exercise inducement transaction, raising approximately $3.6 million in gross proceeds. Holders agreed to exercise Existing Warrants for cash to purchase an aggregate of 7,451,920 shares of common stock at a reduced exercise price of $0.48 per share.

In return, the company issued new Class H Inducement Warrants to purchase up to 14,903,840 shares of common stock at an exercise price of $0.60 per share, exercisable for five years after the stockholder approval date. Ladenburg Thalmann & Co. Inc. acted as placement agent, receiving about $285,000 in fees, $50,000 for expenses, and about $26,000 as a management fee, plus additional placement agent warrants. All new warrants and underlying shares were issued in a private, unregistered offering under Section 4(a)(2) of the Securities Act.

AIM ImmunoTech Inc. entered into a warrant exercise inducement agreement with holders of existing warrants covering up to 8,719,928 shares of common stock. Holders agreed to exercise these warrants for cash at a reduced exercise price of $0.48 per share.

In return, the company will issue new Class H Inducement Warrants to purchase up to 17,439,856 shares of common stock at $0.60 per share, with a five-year term starting on the stockholder approval date. If all existing warrants are exercised in full, AIM ImmunoTech expects to receive approximately $4.20 million in gross proceeds for working capital and general corporate purposes.

The company engaged Ladenburg Thalmann as placement agent, agreeing to an 8.0% cash fee on aggregate gross proceeds, a 0.75% management fee, reimbursement of up to $50,000 of expenses, and issuance of placement agent warrants for up to 6% of the exercised shares. The Inducement Warrants were issued under a Section 4(a)(2) exemption and the related shares will be registered for resale after closing.

AIM ImmunoTech Inc. entered into Amendment No. 1 to its Equity Distribution Agreement with Maxim Group LLC, which serves as its exclusive sales agent for an at-the-market stock offering. The original agreement covered issuance and sale of up to $3,000,000 of common shares.

The amendment removes the limitation on the amount of shares that may be sold under the agreement, allowing additional sales under the company’s effective shelf registration statement on Form S-3 and related prospectus. AIM is also filing a new prospectus supplement to increase the number of shares that may be offered and sold through this at-the-market program.